Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Unusually-High Trading Volume After Analyst Upgrade

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw strong trading volume on Wednesday after DZ Bank upgraded the stock from a hold rating to a strong-buy rating. 5,162,483 shares changed hands during mid-day trading, an increase of 301% from the previous session’s volume of 1,287,501 shares.The stock last traded at $11.3648 and had previously closed at $11.05.

BAYRY has been the subject of a number of other research reports. UBS Group raised shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. Zacks Research raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Bayer Aktiengesellschaft presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Down 1.6%

The company has a quick ratio of 0.63, a current ratio of 1.01 and a debt-to-equity ratio of 1.22. The firm’s 50-day moving average price is $11.29 and its 200 day moving average price is $11.09. The firm has a market cap of $43.60 billion, a P/E ratio of -17.34, a price-to-earnings-growth ratio of 3.61 and a beta of 0.62.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.15. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.74%. The firm had revenue of $15.73 billion for the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, research analysts expect that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.